Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Veratrine is a **mixture of alkaloids** obtained primarily from the seeds of *Schoenocaulon officinale* (sabadilla), and historically sometimes from other plants in the Veratrum genus. This mixture contains mostly **cevadine** and **veratridine**, along with other minor alkaloids. It appears as a white or greyish-white powder, very slightly soluble in water but more soluble in solvents like alcohol, ether, and chloroform[1][5]. Veratrine is **not a single, well-defined compound**, but rather an amorphous, variable mixture[1]. Its pharmacological actions are primarily due to **interaction with voltage-gated sodium channels**, leading to increased nerve and muscle excitability, tingling, and numbness when applied topically, and potentially causing severe toxic effects with systemic exposure[1][2][4]. Veratrine has been used **externally for neuralgia** as an analgesic and counterirritant, and as a **parasiticide** (notably for lice), but is largely obsolete in medical use due to its **toxicity**[1][2][4]. It continues to find use as a **botanical insecticide** due to its neurotoxic actions on pests[4]. Internally, its use is considered unsafe because of severe irritant and toxicological effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on veratrine.